Coherus Oncology (CHRS) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Coherus Oncology (CHRS) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 144.84% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Coherus Oncology | 194.37 Mn | 27.32 Mn | 8.50 Mn | 73.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.61% |
| Dec 31, 2025 | 29.02% |
| Sep 30, 2025 | 28.13% |
| Jun 30, 2025 | 106.71% |
| Mar 31, 2025 | 54.30% |
| Dec 31, 2024 | 53.47% |
| Sep 30, 2024 | 43.52% |
| Jun 30, 2024 | 50.40% |
| Mar 31, 2024 | 44.04% |
| Dec 31, 2023 | -116.90% |
| Sep 30, 2023 | -49.81% |
| Jun 30, 2023 | -39.01% |
| Mar 31, 2023 | -60.43% |
| Dec 31, 2022 | -51.82% |
| Sep 30, 2022 | -55.37% |
| Jun 30, 2022 | -60.42% |
| Mar 31, 2022 | -68.72% |
| Dec 31, 2021 | 9.97% |
| Sep 30, 2021 | 13.16% |
| Jun 30, 2021 | 11.87% |